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INDICATIONS, EFFICACY AND OUTCOMES OF 
PARS PLANA VITRECTOMYIN DIABETIC RETINOPATHY 
AIM: 
 To study the various indications, anatomical results, functional visual 
outcomes, and safety of pars plana vitrectomy (PPV) in complications of proliferative 
diabetic retinopathy (PDR). 
Materials and Methods: 
 This was a prospective interventional study performed on patients presenting at 
the Retina Clinic of a tertiary care eye hospital in Tamil Nadu between April 2012 and 
June 2013.  All eyes undergoing PPV for complications of PDR and having adequate 
follow up were included. Data collected included indications for PPV, type of surgery 
performed, intra and post-operative complications, anatomical outcomes and visual 
results following surgery. 
Results: 
 47 eyes of 46 patients were included in the study. Most common indications for 
surgery were non-clearing vitreous hemorrhage and tractional retinal detachment 
(TRD) threatening the macula. Visual acuity improved significantly following surgery 
across all indications for surgery (p=0.003). Visual acuity continued to improve 
during follow-up period (p=0.00004). Rate of visual recovery was slower with eye 
with TRD as compared to other indications. Retina was attached at last follow up in 
89% of eyes.  Most common complications encountered were 8% eyes had severe 
intraoperative bleeding and 17% eyes had iatrogenic retinal break, post-operatively 
6% of eyes developed recurrent vitreous hemorrhage and retinal break and one eye 
developed combined rhegmatogenous and tractional retinal detachment.  
Conclusions: 
 PPV in eyes with visual loss due to complications of PDR can offer significant 
improvement in visual acuity. However, surgery in these eyes may be associated with 
vision threatening complications. 
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INTRODUCTION 
Diabetes mellitus (DM) is a group of metabolic disease which 
presents with high blood sugar usually due to inadequate secretion of 
insulin. The high blood sugar leads to symptoms such as polyuria, 
polydipsia, and polyphagia. 
 
There are three main types of diabetes mellitus 
• Type 1 DM or insulin-dependent DM is due to the failure of the 
body to produce insulin 
• Type II DM or non- insulin-dependent DM (NIDDM) is due to the 
failure of cells to use the produced insulin 
• A third type Gestational diabetes, occurs in pregnant women without 
previous diagnosis of diabetes 
 
Diabetic retinopathy is a complication of diabetes. It is becoming 
one of the leading causes of newly-diagnosed legal blindness amongst the 
working class people (National Diabetes Data group, 1995)1. 
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In a study in India, 52% of patients with NIDDM over a 25- year 
duration were found to suffer from diabetic retinopathy ( 41.7% from non 
– proliferative diabetic retinopathy and 10.3% from proliferative diabetic 
retinopathy) ( Mohan et al.)2.  
 
The common causes of visual impairment in diabetic retinopathy are 
macular edema and complications of proliferative diabetic retinopathy. 
Type 2 DM is commonly associated with diabetic retinopathy with 
macular edema  (Klien et al.)3. 
 
Diabetic maculopathy is the commonest cause of visual impairment 
in diabetic patients, particularly type 2 diabetes. It is characterized by 
foveal edema, exudates or ischemia. Diffuse retinal edema is due to 
extensive capillary leakage, and localized edema due to focal leakage from 
microaneurysms and dilated capillary segments4. Further accumulation of 
fluid in the fovea leads to cystoid macular edema (CME). 
 
Diabetic macular edema is the result of retinal thickening due to 
exudation from incompetent retinal capillaries; this can also occur 
peripheral to the retina which is not vision-threatening. The Early 
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Treatment Diabetic Retinopathy Study (ETDRS)5 coined the term 
“clinically significant macular edema” (CSME) to refer to: 
• retinal thickening occurring at the centre of the macula; or 
• retinal thickening and hard exudates occurring within 500 microns 
of the centre of the macula; or 
• retinal thickening greater than or equal to 1 disc area, with any part 
of which is within 1 disc diameter of the centre of the macula. 
 
Development and progression of diabetic retinopathy can be 
prevented by strict control of diabetes and other associated risk factors, 
such as hypertension6-8. In its initial stages, diabetic retinopathy may not 
require treatment but, in the presence of CSME and proliferative changes, 
treatment is essential to prevent visual loss and to restore vision. Initial 
treatment often includes laser photocoagulation (focal, grid or panretinal 
laser photocoagulation) or the use of intravitreal anti-vascular endothelial 
growth factor (anti-VEGF) agents or  corticosteroids. In some cases, 
surgical intervention in the form of pars plana vitrectomy (PPV) becomes 
inevitable.  
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Diabetic macular edema associated with a taut posterior hyaloid is 
an important and well-known indication for PPV. Additionally, diffuse 
diabetic macular edema without posterior vitreous detachment, where the 
posterior hyaloid is not taut or thickened, can benefit from vitrectomy, with 
visual improvement in 53% of eyes9. Yet another indication is a non-
clearing dense vitreous hemorrhage of more than 3 months duration with 
no prior laser photocoagulation, where the extent of proliferation is 
extensive and the fellow eye exhibits rapidly – progressive loss of vision, 
or in the presence of rubeosis with recent vitreous hemorrhage without 
laser photocoagulation. Early surgical intervention in dense premacular 
hemorrhage is reported to prevent proliferation10. 
 
Tractional retinal detachment is due to fibrous transformation and 
contraction of neovascular tissue which causes macula-threatening 
traction. Early vitrectomy is indicated in type 1 DM associated with media 
opacities that prevent laser photocoagulation, and in the presence of rapid 
progression in the fellow eye. Visual prognosis is poor if macular 
detachment is of more than 6 months duration11.  
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Another major indication for PPV in proliferative diabetic 
retinopathy (PDR) is combined tractional and rhegmatogenous retinal 
detachment. The rhegmatogenous component is due to fibrovascular 
proliferation, causing retinal break(s). These breaks commonly occur on 
old chorioretinal scars and at the base of vitreoretinal adhesions. 
 
In anterior hyaloid proliferation unresponsive to peripheral confluent 
photocoagulation or in significant recurrent vitreous hemorrhage despite 
maximal panretinal photocoagulation, early intervention through PPV 
decreases the risk of peripheral retinal detachment, hypotony and 
phthisis12.  
 
PPV in diabetic retinopathy can be associated with a significant risk 
of complications. Intraoperative complications of vitrectomy include 
peripheral retinal dialysis, peripheral tears, vitreous or retinal incarceration 
in the wound, corneal erosions (common in diabetics), filamentary 
keratitis, bullous keratopathy,  damage to the lens by direct touch of 
instruments, and the solutions used; intraoperative hemorrhage, retinal 
tears, retinal detachment and posterior breaks can also occur13.  
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Post-operative complications after PPV include residual hemorrhage 
from surgery, retained blood within vitreous, continued hemorrhage from 
bleeding sites, retinal traction, bullous retinal detachment, anterior hyaloid 
proliferation, progression of cataract, corneal decompensation, hypotony, 
post-operative glaucoma and endophthalmitis14,15. 
 
Recurrence of post-operative vitreous hemorrhage in PDR ranges 
from 29 – 75%16. It commonly occurs within 6 months following surgery 
and is often of unknown cause. Delayed post-operative hemorrhage is due 
to anterior hyaloid proliferation17. Other causes include 
fibrovascularization from the sclerotomy site, recalcitrant fibrovascular 
proliferation, and neovascularization of the iris and angle18. 
 
The Diabetic Retinopathy Vitrectomy Study (DRVS), the results of 
which were published in DRVS report 3 in journal Ophthalmology in 
1988, was a prospective, randomized clinical trial that studied the role of 
vitrectomy in managing eyes with severe PDR. Two outcome 
measurements in DRVS were percentage of eyes with 10/20 and 10/50 
visual acuity, on DRVS-standardized visual acuity charts at 2 and 4 year 
follow up examination. The DRVS evaluated the benefit of early (1-6 
7 
months after onset of vitreous hemorrhage) versus late (at 1 year) 
vitrectomy for eyes having very severe vitreous hemorrhage and visual 
loss (≤5/200). Patients with type 1 diabetes with severe vitreous 
hemorrhage clearly demonstrated the benefit of early vitrectomy, but no 
advantage was found in mixed or type 2 patients. The DRVS also showed 
an advantage for early vitrectomy compared with conventional 
management in eyes with very severe PDR. 
 
Advances in vitreoretinal surgery, including routine use of endolaser 
during surgery, have led to modifications of certain recommendations of 
the DRVS. Patients with preexisting, well-placed, complete panretinal 
photocoagulation treatment during the phase of vitreous hemorrhage can 
be under long-term observation. If panretinal photocoagulation has not 
been performed, early intervention is recommended in patients with 
vitreous hemorrhage secondary to PDR regardless of type of diabetes19, 20.  
 
It is clear that PPV is an important surgical option when managing 
patients with PDR. However, further information is needed from centers in 
India dealing with unique problems faced by Indian diabetic patients, since 
India is considered to be the “Diabetic Capital of the world”. In the present 
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investigation on which this dissertation is based, an attempt has been made 
to document various indications for PPV in patients presenting with 
diabetic retinopathy (DR) at a tertiary eye care facility in Tamilnadu, India. 
The anatomical results and functional visual outcomes following PPV in 
eyes with DR, and putative factors influencing the results obtained, have 
also been determined. Very importantly, the safety of PPV in eyes with DR 
has been clarified by documenting intraoperative and postoperative 
complications, and elucidating factors that possibly contribute to such 
complications. 
 
Aim of the Study 
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AIM OF THE STUDY 
1. To document the various indications for pars plana vitrectomy in 
patients presenting with diabetic retinopathy at a tertiary care facility 
in India 
2. To determine the anatomical results and functional visual outcomes 
following pars plana vitrectomy in eyes with diabetic retinopathy, 
and to elucidate factors possibly influencing the results obtained 
3. To clarify the safety of pars plana vitrectomy in eyes with diabetic 
retinopathy by documenting intraoperative and post-operative 
complications, and to elucidate factors possibly contributing to such 
complications.  
 
 
 
 
Review of Literature 
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REVIEW OF LITERATURE 
Diabetic retinopathy is a leading cause of severe loss of visual acuity 
in developed countries. When compared to non diabetic populations about 
25% of patients with diabetes have sight-threatening retinopathy, with 
legal blindness (best corrected visual acuity of 20/200 or worse) being 25 
times more common (Kahn et al.)21. 
Fundamentally, diabetes mellitus causes abnormal glucose 
metabolism which is due to decreased level of insulin or their activity. 
Increased levels of glucose in blood are said to produce structural and 
physiologic effect on retinal capillaries which makes them incompetent 
both functionally and anatomically. 
Continuous increase in blood glucose levels in certain tissues sends 
the excess glucose into the aldose reductase pathway, where sugar is 
converted into alcohol (eg, glucose into sorbitol, galactose to dulcitol). 
Increased levels of sorbitol affects the intramural pericytes of retinal 
capillaries, which eventually leads to the loss of their main function (that 
is, autoregulation of retinal capillaries)22. This results in weakness and 
eventual saccular outpouching of retinal capillary walls namely, 
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microaneurysm formation. These microaneurysms are the earliest 
detectable signs of retinopathy in DM. It ultimately leads to vascular 
endothelial damage and hypoxia to the retinal tissues. 
In patients with proliferative diabetic retinopathy (PDR), nocturnal 
intermittent hypoxia/reoxygenation that results from sleep-disordered 
breathing may be a risk factor for iris and/or angle neovascularization23.  
Neovascularization is commonly seen between the perfused and 
nonperfused retina, mostly along the blood vessels and at the optic disc. 
The new vessels, which are fragile and highly permeable, grow along the 
space in the posterior hyaloid face and surface of the retina. These delicate 
vessels are damaged easily by traction from the vitreous, and cause 
vitreous or preretinal hemorrhage. These new blood vessels are usually 
responsible for the formation of small amount of fibroglial tissue. When 
the density of the neovascular frond increases, the fibrous tissue formation 
also increases. Later, these new vessels regress, leaving behind a fibrous 
tissue adherent to the retina and the posterior hyaloid, which causes retinal 
edema, retinal heterotropia, tractional retinal detachment and retinal tears 
as a result of vitreous contraction. 
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The Early Treatment Diabetic Retinopathy Study (ETDRS), initiated 
in 1980 divided 3711 patients who presented with severe nonproliferative 
or early proliferative diabetic retinopathy in both eyes in to different 
groups. Patients were randomly divided into different groups of which 1 
had aspirin 650 mg/day or placebo. One eye of the entire patients was 
subjected randomly to early photocoagulation and the other eye did not 
receive photocoagulation. Patients were followed-up at every 4 months 
interval, and photocoagulation was given in eyes that developed high-risk 
proliferative retinopathy of the control eyes. The study concluded that 
aspirin had no effect on progression of retinopathy or in vitreous 
hemorrhage. The risk of development of severe visual loss or eyes 
requiring vitrectomy, was low in eyes which did not receive 
photocoagulation (6% at 5 years) and the risk of progression was reduced 
by early photocoagulation (4% at 5 years). 208 patients underwent 
vitrectomy during the study period of around 9 years.  With regular follow-
up and timely (panretinal) photocoagulation the 5-year collective rate of 
pars plana vitrectomy in ETDRS patients was 5.3%. Use of aspirin did not 
have any effect on the rate of vitrectomy24.  
Vitreous hemorrhage is a serious complication of proliferative 
diabetic retinopathy, since it provides evidence of the severity of 
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proliferative retinopathy at stake and precludes laser photocoagulation. 
However, panretinal photocoagulation remains possible in some cases of 
moderate vitreous hemorrhage especially using longer wavelengths such as 
krypton red25; cryotherapy under ophthalmoscopic control may be an 
alternative to panretinal photocoagulation26. Development of pars plana 
vitrectomy, however, constitutes the defining breakthrough in the 
management of severe vitreous hemorrhage. Although pars plana 
vitrectomy was first reserved for massive, long-standing vitreous 
hemorrhage, improvements in instrumentation and techniques, as well as 
observations of the favorable effect of vitrectomy on the progression of 
proliferative retinopathy have led to an extended array of indications for 
this procedure. 
In addition to severity and duration of visual loss, the main 
arguments for performing pars plana vitrectomy are bilaterality of lesions, 
lack of previous panretinal photocoagulation, iris neovascularization, Type 
1 diabetes, and severity of fibrovascular proliferation (Mathis A et al.)27.  
The surgical management of coexisting cataract and vitreoretinal 
disease has been controversial, particularly for eyes with a history of PDR 
or chronic uveitis. Forster et al., (1993) retrospectively studied the results 
of combined extracapsular cataract extraction (ECCE), posterior chamber 
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intraocular lens (PC-IOL) implantation, and pars plana vitrectomy in 20 
eyes of 16 patients. The indications for combined vitrectomy included 
dense, non-clearing vitreous hemorrhage (attributed to PDR) in 10 eyes, 
age-related macular degeneration in two, and trauma in one. The remaining 
seven eyes underwent pars plana vitrectomy to remove inflammatory 
vitreous cells and debris associated with chronic uveitis.  In this series of 
patients, the follow-up ranged from 4 to 32 months (average, 17.4 months). 
Visual acuity was found to have improved in 19 eyes (95%) to 20/100 or 
better in 12 eyes (60%); the improvement ranged from 1 to 13 Snellen 
lines (average, 4.9 lines). The postoperative visual acuity improvement 
averaged 7.5 Snellen lines for eyes with chronic uveitis, 7.0 lines for those 
with age-related macular degeneration, and 3.3 lines for those with a 
history of PDR. The postoperative visual acuity was less than 20/100 in 
eight eyes (40%); these results were mostly attributed to macular changes 
associated with the underlying ocular disease. The authors concluded that 
combined ECCE/PC-IOL implantation and pars plana vitrectomy is a well-
tolerated surgical procedure for diabetics, which can provide clear anterior 
and posterior segment media28. 
In another setting, Neely and Scroggs conducted a retrospective 
study of  patients who had repeat vitrectomy for post-operative diabetic 
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vitreous hemorrhage (PDVH) and who also received peripheral retinal 
cryotherapy in phakic patients. Final Best corrected visual acuity (BCVA) 
after repeat vitrectomy with peripheral retinal cryotherapy was compared 
to BCVA at the time and before in case of PDVH. Anatomic outcomes 
studied were retinal attachment, vitreous hemorrhage, iris new vessel 
formation, development of cataract, and anterior hyaloidal 
neovascularization. Based on their results, they opined that in case of non-
clearing PDVH in phakic eyes, peripheral retinal cryotherapy ( augmented, 
if possible with posterior pole endolaser photocoagulation) can be used to 
supplement previous retinal photocoagulation during repeat vitrectomy, 
since this technique leads to a more stable retina and better visual outcome 
in most treated eyes. These authors concluded that transscleral peripheral 
retinal cryotherapy was frequently feasible to use in situations (such as 
media opacity) where peripheral retinal endolaser or indirect laser 
photocoagulation could not be done29.  
Yeh et al. sought to study whether cryotherapy of the sclerotomy 
sites and anterior retina would prevent fibrovascular ingrowth (FVIG) at 
sclerotomy sites and recurrent vitreous hemorrhage in patients with PDR. 
Cases were divided into those undergoing anterior peripheral retinal 
cryotherapy (ARC) in addition to panretinal endolaser treatment, or having 
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endophotocoagulation, ARC, and cryotherapy on the 3 sclerotomy sites, or 
panretinal endolaser treatment alone. Ultrasound biomicroscopy of the 3 
sclerotomy sites was performed at or later than 2 months, and the findings 
obtained were differentiated into 4 groups: FVIG, gap, well-healed, and 
vitreous incarceration. History and management of recurrent severe 
vitreous hemorrhage were recorded. The occurrence of recurrent 
postoperative vitreous hemorrhage was strongly correlated with presence 
of fibrovascular ingrowth. The authors concluded that ARC along with 
cryotherapy of sclerotomy sites might be useful additional measure for 
formation of FVIG and prevention of recurrent vitreous hemorrhage in 
diabetics30. 
En bloc perfluorodissection (EBPD), is a surgical technique that 
helps in removal of posterior hyaloid and epiretinal membrane, it is 
performed to separate the epiretinal membrane from the adjacent retina by 
injecting perflurocarbon liquid between the posterior hyaloid and the 
retina.   Aravelo et al. (2008) described the technique and sought to 
demonstrate the same during vitrectomy in eyes with tractional retinal 
detachment in PDR.   None of the patients studied developed ocular 
hypertension or any other inflammation, and all eyes had good anatomical 
and functional success. In 14 eyes (24.5%), the best corrected visual acuity 
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(BCVA) remained stable, and in three (5.2%) eyes, BCVA decreased (≥ 2 
ETDRS lines). Final BCVA was 6/12 or better in 25%, between 6/18 and 
5/60 in 47%, and worse than 5/60 in 28%. One eye developed phthisis 
bulbi (1.7%), four (7%) eyes had iatrogenic retinal breaks, four eyes had 
vitreous hemorrhage requiring another surgery, and cataract in 15 (26.3%) 
eyes. Thus EBPD can be performed during vitrectomy in eyes with 
tractional retinal detachment in PDR31. 
Pokroy et al., (2011) retrospectively assessed the safety and 
effectiveness of preoperative intravitreal bevacizumab before vitrectomy in 
case of proliferative diabetic retinopathy with tractional retinal detachment. 
All patients with this condition who had undergone 3-port 
20-gauge vitrectomy (primarily performed by one surgeon) over a 5 year 
period were included. Eyes that had received intravitreal bevacizumab 
were compared with those that had not. Ninety-nine eyes of ninety patients 
were included in the study. In all, 34 patients had received intravitreal 
bevacizumab on an average of 11.5 (range, 3-30) days previtrectomy; 
while the visual acuity had improved from 20/617 to 20/62 in the eyes that 
had received bevacizumab, the improvement was from 20/440 to 20/80 in 
the eyes that had not received bevacizumab. In younger patients  
(≤ 40 years), time taken for performing the surgery was found to be 
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significantly shorter and a trend to better visual acuity was noted in the 
eyes that had received intravitreal bevacizumab, prompting the authors to 
conclude that pre-operative bevacizumab might be a useful adjunct 
to vitrectomy for severe proliferative diabetic retinopathy complicated by 
tractional retinal detachment in young patients with diabetes32.  
Zhao et al., performed a meta-analysis of six randomized controlled 
trials and one comparative study with a view to compare vitrectomy alone 
(142 eyes, control group) with vitrectomy with intravitreal bevacizumab 
pretreatment (139 eyes) for severe diabetic retinopathy. The occurrence of 
intraoperative bleeding and frequency of endodiathermy were found to be 
less in bevacizumab pretreatment group than in the group which underwent 
vitrectomy alone; the bevacizumab pretreatment group had markedly less 
surgical time than the control group. There was a significantly shorter 
blood reabsorption time, incidence of recurrent vitreous hemorrhage was 
almost significantly less, and final BCVA was markedly better in the eyes 
that had received bevacizumab than in those that had not. Other 
complications, such as final retinal detachment, and resurgery, were not 
statistically significant between the groups33.  
Sato et al., compared outcomes and procedures done, including the 
time taken for recovery, in eyes with PDR that had undergone 25-gauge 
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microincision vitrectomy surgery (87 eyes, 55 patients) with those that had 
undergone 20-gauge vitrectomy (72 eyes, 53 patients). There were no 
marked differences between surgical procedures or cases with 
postoperative complications between those that had undergone 20-gauge or 
those that had under gone 25-gauge vitrectomy. The anatomical success 
rate in both the groups was 100%. The BCVA at the end of 6 months after 
final vitrectomy was much better than the preoperative reading for both 
types, and was not different between both the groups. Interestingly the 
average duration of hospital stay was 19.5 days after 20-gauge vitrectomy, 
which was much longer than the 11.0 days after 25-gauge vitrectomy. The 
authors concluded that their results indicated that 25-gauge microincision 
vitrectomy surgery were not different from 20-gauge vitrectomy in eyes 
with PDR in terms of anatomical and functional outcomes. However, after 
25-gauge microincision vitrectomy surgery the recovery period is shorter 
and less traumatic than 20-gauge vitrectomy34.  
Gupta et al. (2012) sought to evaluate anatomical outcome and eyes 
with visual acuity of ≤ 0.3 log MAR in patients who had undergone 20G 
PPV over a 17-month period for complications of PDR such as severe 
vitreous hemorrhage and tractional retinal detachment; Three hundred and 
forty six eyes of 249 patients with follow-up period of 1.5 years were 
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analyzed. Flat retina was observed in 95.3% of eyes during final follow-up; 
136 eyes out of three hundred and forty six (39.4%) eyes had final visual 
acuity of 6/12 and 129 (37.3%) had 6/60 by snellen; 50 out of 181 (27.6%) 
eyes with tractional retinal detachment and 84eyes out of 165 (50.9%) with 
non clearing vitreous hemorrhage achieved a final visual acuity of ≤ 0.3 
logMAR (Snellen 6/12). Sixty three percent of eyes showed ≥ 0.3 logMAR 
improvements from pre-operative to last follow-up. Both preoperative 
visual acuity and final postoperative visual acuity improved every year 
significantly. The per-operative complication which was encountered 
frequently was iatrogenic retinal tear in 28.4%, which was a risk factor for 
the development of post-operative retinal detachment. During the 
procedure silicone oil was used in 5.2% of patients. Non-clearing post-
vitrectomy hemorrhage needed removal in 9.2% of eyes35.  
End-stage diabetic eye disease is an important cause of severe visual 
impairment in the working-age group. Gupta et al. identified patients who 
had undergone vitrectomy over a three-year period because of diabetes-
related complications in South East London. The prevalence of people 
requiring vitrectomy in that area was two per thousand diabetics. 185 eyes 
of 158 patients underwent vitrectomy during this period (Fifty one Afro-
Caribbeans, seventeen South Asians, seven from other ethnic groups and 
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eighty three Caucasians). 58 patients presented with type I diabetes (mean 
duration 23 years) and 100 with type II diabetes (mean duration 16.5 
years). 109 eyes with tractional retinal detachment, 68 eyes with non-
clearing vitreous hemorrhage, and eight eyes with other causes underwent 
vitrectomy. Finally, at the end of 12 months 50% of eyes with tractional 
retinal detachment and non clearing vitreous hemorrhage, and 87% of the 
eyes with non-clearing vitreous hemorrhage improved by minimum of 3 
ETDRS lines. Poor visual success was attributed to (i) duration of diabetes 
being longer, (ii) patient using insulin, (iii) presence of heart disease, 
(iv) delay in undergoing surgery, and (v) failure to come for follow-up. 
Use of intravitreal bevacizumab pre-operatively in eyes undergoing 
vitrectomy with tractional retinal detachment had some beneficial effect on 
the maculopathy if present and post -operatively the need for laser 
photocoagulation was less, but did not have any effect on vitreous 
hemorrhage that occurred post-operatively. The authors concluded that 
visual outcomes was significantly better in their study compared with the 
results from the Diabetic Vitrectomy Study36.  
Newer horizons have been achieved in vitreoretinal surgery due to 
technological up gradation in the instruments used for the surgery. The 
main aim of modern day vitreoretinal surgery is to achieve the best 
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possible outcome by the least possible surgical intervention. The advances 
in surgery include transconjunctival sutureless vitrectomy (23 and 25 G) 
and the availability of  high speed cutters, microcannulas, insertion trocars, 
xenon light source, wide angle fundus viewing systems such as binocular 
indirect operating microscope and erect indirect binocular ophthalmic 
system, pulsed electron avalanche knife, perflurocarbon liquids, expansile 
gases, and anti – VEGF adjuncts37. 
Transconjunctival sutureless vitrectomy provides earlier visual 
improvement (as early as 7 days) and less surgically- induced astigmatism 
about -1.50 Dioptre than conventional vitrectomy38. One study reported 
that there were fewer complications in 23G transconjunctival sutureless 
vitrectomy and an improved final visual acuity of 20/70, (from a pre 
operative visual acuity of 20/150) with a  mean follow up of 6.5 months 
(range 3-9 months), thus providing improved outcome and prognosis39.  
Challenges that remain ahead in vitrectomy are to minimize 
iatrogenic trauma, to make the procedure safe and reproducible and to 
develop techniques that help avoid surgery (such as chemical induction of 
a posterior vitreous detachment). 
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In the present investigation, the various investigations for parsplana 
vitrectomy in patients presenting with diabetic retinopathy have been 
documented; the anatomical results and functional outcomes, the 
intraoperative and post-operative complications, and factors contributing to 
the results and complications have also been elucidated. 
Materials & Methods 
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MATERIALS AND METHODS 
This was a prospective interventional study performed on patients 
presenting at the Retina Clinic of a tertiary care eye hospital in Tamil Nadu 
between April 2012 and June 2013. This study was approved by the 
Institutional Ethics Committee. 
Patients were recruited in the study if they (Inclusion Criteria): 
1. Provided informed written consent to participate in the study 
2. Presented with proliferative diabetic retinopathy and were willing to 
undergo pars plana vitrectomy to manage complications 
 Patients were excluded if any one of the following occurred 
(Exclusion Criteria): 
1. Did not provide informed consent 
2. Presented with other retinal vascular disorders, epiretinal membrane 
or macular hole not attributable to diabetes 
3. Suffered from pre-existing conditions such as age-related macular 
degeneration and advanced glaucoma that were deemed capable of 
adversely affecting visual outcomes 
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4. Suffered from a medical condition for which pars plana vitrectomy 
was contraindicated. 
 Data of patients who had not completed a three month follow-up 
were excluded from final analysis. 
A complete medical and ocular history was taken at the baseline 
visit, including duration of diabetes, treatment history, control of diabetes 
and other co-existent morbidities.  All the patients underwent a detailed 
ophthalmic examination which included: 
1. Best corrected visual acuity for distance and near vision ( Snellen’s 
chart for distance vision and Snellen’s chart for near vision) 
2. Slit lamp biomicroscopy 
3. Fundus examination (+90D lens) and indirect ophthalmoscopy 
4. Intraocular pressure measurement (Goldmann’s applanation 
tonometry) 
5. Fundus photography 
6. Fundus fluorescein angiography 
7. Optical coherence tomography (OCT) for detection of macular 
edema, vitreomacular traction, epiretinal membranes, taut posterior 
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hyaloids and partial or full thickness macular holes, and for 
assessment of degree and extent of posterior vitreous detachment. 
OCT was performed on the Zeiss® Cirrus HD OCT ™ (Zeiss 
Meditec, Dublin, CA, USA) using a macular cube or Raster scan 
protocol 
8. Ultrasonography B scan was performed to assess the vitreous and 
retinal status if media opacities precluded a clear view of the fundus. 
 Eyes were considered for pars plana vitrectomy if any of the 
following lesions was present: 
a) non-clearing vitreous hemorrhage of more than a month’s duration; 
b) vitreous hemorrhage producing severe visual loss (visual acuity less 
than 5/60) in one-eyed patients; 
c) tractional retinal detachment affecting the fovea or within 0.5 disc 
dioptres  of the fovea; 
d) combined rhegmatogenous and tractional retinal detachment; 
e) thickened and taut posterior hyaloids significantly affecting visual 
acuity;  
f) vitreomacular traction; and 
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g) persistent diabetic macular edema unresponsive to laser and 
intravitreal therapy. 
 The indication for pars plana vitrectomy was recorded and all cases 
were operated upon by one of three experienced vitreoretinal surgeons. 
Procedure 
All patients received an explanation of the procedure and its possible 
complications, and written informed consent was obtained. 
In patients with active neovascularization or fresh vitreous 
hemorrhage, bevacizumab (2.5mg/0.1ml) was given intravitreally 1 or 2 
weeks prior to surgery. 
All patients were operated on under local anesthesia with close 
monitoring of the patient’s medical condition by an anesthesiologist with 
the titration of 50:50 mixture of 2% lidocaine (combined with 1 in 100000 
adrenaline and hyaluronidase) and 0.75% bupivicaine (Neon laboratories 
ltd, Mumbai, India) as the local anesthetic agent given as a peribulbar 
injection. The eye was prepared by cleaning the skin and eye lashes with 
5% povidone- iodine (Aurodine, Aurolab, Madurai, India) solution, and 
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instillation of 5% povidone – iodine in the conjunctival cul-de-sac. The eye 
was draped and all the surgeries were performed. If a visually significant 
cataract was present or if cataract prevented adequate visualization of the 
retina, a manual small incision cataract surgery or phacoemulsification was 
performed, with implantation of a posterior chamber intraocular lens. A 
standard 3 port 20 gauge pars plana vitrectomy was done using the Alcon 
Accurus ® vitrectomy system (Alcon Surgicals, Texas, USA). 
Sclerotomies were made, 3.5 mm posterior to the limbus in pseudophakic 
eyes and 4mm in phakic eyes, using a 19 gauge microvitreoretinal blade; a 
4mm long infusion cannula was then inserted at the sclerotomy site inferior 
to the lateral rectus insertion with the infusion closed. The cannula was 
fixed with a 8-0 vicryl mattress suture and the tip of the cannula was 
visualized clearly before the infusion was opened. The other 2 sclerotomies 
were placed 150- 160º apart just superior to the meridian of the horizontal 
rectus insertions. One port carried the fibreoptic light source and the other 
was used for the instruments and the vitrector. With the non contact wide 
angle viewing system binocular indirect operating microscope (BIOM) in 
place, the eye was manipulated with a bimanual technique with two 
instruments. Core vitrectomy was done, vitreous hemorrhage was cleared 
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and a posterior vitreous detachment was induced if not present. The 
posterior hyaloid was first opened over the attached retina; the opening of 
the posterior hyaloid was then enlarged until the retina was visualized. If 
the blood in the subhyaloid obscured the retina, it was removed with the 
help of a silicone-tip suction needle. All the fibrovascular membranes were 
removed by horizontal and vertical scissors with the combination of 
segmentation and delamination technique. Bleeders were cauterized by 
endocautery. Perflurocarbon liquids (PFCL) were used to stabilize the 
retina prior to membrane removal in extensive tractional retinal 
detachments. Any preexisting retinal breaks or iatrogenic breaks were 
treated by endolaser photocoagulation all around the break using the  
Iridex™ 810nm laser with endodelivery system (Iridex corporation, 
California, USA).  If rhegmatogenous retinal detachment was present, the 
retina was flattened using PFCL or by fluid air exchange. If panretinal 
photocoagulation was inadequate, it was completed on the table. Patients 
who needed internal tamponade were treated either with silicone oil or 
intraocular gases, such as 20% sulfur hexafluoride (SF6) and 16% 
perfluropropane(C3F8). In certain cases, pars plana lensectomy was done 
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during surgery in cases requiring membrane dissection in the vicinity of 
the vitreous base. 
At the end of the procedure, the 2 sclerotomy sites were closed by  
8.0 vicryl sutures and a fluid-air exchange or fluid- gas exchange or with 
silicone oil was done and the third port was also closed. Intraoperative 
complications, such as iatrogenic breaks, excessive bleeding, inability to 
completely remove membranes and damage to the lens, were recorded. 
The patient was advised to maintain proper  positioning depending on 
location of breaks and macular status. All patients were started on a 
combination of antibiotic and steroid eye drops (Ocepred eye drops, 10mg 
prednisolone/3mg ofloxacin, Sun Pharma, India) 6 times a day and 0.5% 
timolol maleate (Timoblu, 0.5% timolol maleate, Lupin pharma, India) 
twice daily, and follow up examination was done at one week, one month, 
and three months. 
At each review visit, the following examinations were performed: 
1. determination of  best corrected visual acuity for distance and near 
vision; 
2. slit lamp biomicroscopy; 
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3. fundus examination (+90D lens) and indirect ophthalmoscopy; 
4. intraocular pressure measurement (Goldmann’s applanation 
tonometry); 
5. fundus photography; and 
6. optical coherence tomography for macular edema. 
The main outcome measures evaluated were changes in visual 
acuity, anatomical results (clearing of vitreous opacities, reattachment of 
retina and resolution of the macular edema) and changes in macular 
thickness. Intraoperative complication rates were analyzed and the 
occurrence of post-operative complications such as secondary glaucoma, 
development of cataract, retinal detachment and rebleed into vitreous 
cavity or development of neovascularization of the anterior segment, was 
also studied. 
 Figure 1.  Alcon Accurus ® vitrectomy system (Alcon Surgicals, Texas, 
USA). 
 
 
 
Figure 2.  Iridex™ 810nm laser with endodelivery system (Iridex 
corporation, California, USA). 
  
 
Figure 3.  Occulus® BIOM (Binocular indirect operating microscope) 
attached to the Zeiss ® Visu 150 Operating microscope.  
 
 
Figure 4.  20 G Vitrectomy probe (top), 20 G endoilluminator  probe 
(middle), Curved endolaser delivery probe (bottom).  
Results 
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RESULTS 
 Over a period of 13 months (May 2012 to May 2013), 81 patients 
underwent pars plana vitrectomy for complications of diabetic retinopathy 
at Joseph Eye Hospital and were considered for inclusion in the study. Of 
these, 34 patients were excluded due to one or more exclusion criteria, 
hence 46 patients (47 eyes) were included in the study 
1.  Demography of patients 
 a.  Gender distribution of the enrolled patients 
 Of the 46 patients enrolled in the study, 26 patients were male and 
20 were females. (Chart-1) 
b.  Age characteristics of the enrolled patients   
 In this study the mean age of the patients was 55.04 ± 9.6 years 
(range 35 to 80 years), with 16 patients (35 %) in the 41 to 50 year age 
group, 14 patients (30 %) in the 61 to 70 year age group and 14 patients 
(26 %) in the 51 to 60 year age group.  (Chart-2) 
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Chart 1.  Gender distribution of patients undergoing pars plana 
vitrectomy for diabetic retinopathy complications 
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Chart 2.  Age distribution of patients undergoing pars plana 
vitrectomy for diabetic retinopathy complications 
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c.  Laterality of study eyes 
 Forty seven eyes presented with complications of diabetic 
retinopathy. Vitrectomy was performed for the right eye in 26 instances 
(55%) and for the left eye in 21 instances (45%). (Chart-3)  
 
Chart 3.  Laterality of study eyes in patients undergoing pars 
plana vitrectomy for diabetic retinopathy complications 
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d.  Duration of diabetes 
In this study, 30 (65 %) of  patients had suffered from  diabetes 
mellitus for between 1 to 10 years duration, 14 (30 %) patients in the study 
had duration of diabetes ranging between 11 to 20 years and one (2 %) 
patient each had suffered from diabetes for 21 to 30 years and 31 to 40 
years, respectively (Table 1; Chart-4). The mean duration of diabetes in 
patients with vitreous hemorrhage was 11.64 ± 7.40 years, and mean 
duration in patients with Tractional retinal detachment was 8.81 ± 4.19 
years, this difference was not statistically significant (‘t’ [d.f :42] = 1.57; 
p=0.13) (unpaired Student’s ‘t’ test). 
 
Table-1  Duration of diabetes in patients undergoing pars plana 
vitrectomy for diabetic retinopathy complications 
Range in years No of Patients Percentage % 
1 – 10 
11 – 20 
21 – 30 
31 – 40 
30 
14 
1 
1 
65 
30 
2 
2 
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Chart 4.  Duration of diabetes in patients undergoing pars plana 
vitrectomy for complications of diabetic retinopathy 
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e.  Co existing morbidity 
In this study of the 46 patients who presented with diabetic 
retinopathy, 24(52%) also had other associated systemic disease. Twenty 
(44%) patients presented with hypertension and diabetes, four (8%) 
patients had ischemic heart disease along with diabetes and 22 (48%) 
patients presented with only diabetes. (Table-2) 
 
Table - 2  Coexisting morbidity in patients undergoing pars plana 
vitrectomy for diabetic retinopathy complications 
Disease No of Patients Percentage % 
Hypertension 
Ischemic heart disease 
Only Diabetes 
20 
4 
22 
44 
8 
48 
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f.  Treatment of diabetes 
In the study, of the 46 patients who were being treated for diabetes, 
40(87%) patients were on oral hypoglycemic agents and 6(13%) patients 
were on insulin. (Chart-5) 
 
Chart 5.  Treatment of Diabetes in patients undergoing pars plana 
vitrectomy for diabetic retinopathy complications 
 
OHA – oral hypoglycemic agents 
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2.  Indications for Vitrectomy 
Of the 47 eyes included in the study 25 (53 %) eyes underwent 
surgery for vitreous hemorrhage, seven (15%) eyes for tractional retinal 
detachment, nine (19%) eyes for tractional retinal detachment with 
vitreous hemorrhage, two (4%) eyes for recalcitrant macular edema, 2 
(4%) eyes for dense non- clearing premacular hemorrhage, one (2%) eye 
for vitreomacular traction and one (2%) eye for vitreomacular traction with 
vitreous hemorrhage (Table-3; Chart-6). 
Table-3  Indications for vitrectomy in patients undergoing pars 
plana vitrectomy for diabetic retinopathy complications 
Indications Number of Eyes 
VH 
TRD 
TRD + VH 
Macular edema 
Premacular hemorrhage 
VMT 
VMT + VH 
25 
7 
9 
2 
2 
1 
1 
 
VH – Vitreous hemorrhage 
TRD – Tractional retinal detachment 
VMT – Vitreomacular traction 
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Chart 6.  Indications for pars plana vitrectomy in patients with 
complications of proliferative diabetic retinopathy 
 
VH- Vitreous hemorrhage 
TRD – Tractional retinal detachment 
VMT – Vitreomacular traction 
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3.  Pre Operative visual acuity  
In this study, mean best corrected visual acuity (BCVA), in 
decimals, prior to surgery was 0.048 ± 0.01 (~3/60). In patients with 
vitreous hemorrhage the average BCVA was 0.019 ± 0.01 (~1/60), in case 
of tractional retinal detachment the average BCVA was 0.070 ± 0.029 
(~4/60), in combined tractional retinal detachment with vitreous 
hemorrhage the BCVA was 0.053 ± 0.03 (~3/60) and in other groups the 
BCVA was 0.133 ± 0.038 (~6/60). These differences were statistically 
significant (one way analysis of variance [ANOVA] Fisher ‘F’ value = 5.1, 
degree of freedom {d.f} = 46; p= 0.004 (Table-4) 
Table-4  Mean pre operative best Corrected Visual Acuity in 
different groups of patients undergoing pars plana 
vitrectomy in diabetic retinopathy complications 
Patient (eye)group 
 
No of eyes Mean BCVA (± 
SEM) 
In Decimals 
Approximate 
Snellens equivalent 
VH 
TRD 
VH + TRD 
Others 
25 
7 
9 
6 
0.019 ± 0.01 
0.070 ± 0.01 
0.053 ± 0.03 
0.133 ± 0.04 
1/60 
4/60 
3/60 
6/60 
Overall mean 47 0.048 ± 0.01 3/60 
VH – Vitreous hemorrhage 
TRD – Tractional retinal detachment 
BCVA-Best corrected visual acuity 
SEM – Standard error of the mean 
Fisher ‘F’ value = 5.1 [d.f=46]; p=0.004 
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4.  Surgery performed  
 In this study, all 47 eyes of 46 patients underwent standard 20G  
3-port pars plana vitrectomy, of which 21 (45%) eyes underwent 
vitrectomy with membrane peeling, endolaser and silicone oil injection, 
seven (15%) eyes underwent vitrectomy with membrane peeling and 
endolaser, six (13%) eyes underwent vitrectomy with endolaser alone, six 
(13%) eyes underwent vitrectomy with intraocular lens implantation, four 
(8%) eyes underwent vitrectomy with intraocular lens implantation, 
membrane peeling and endolaser and three (7%) eyes underwent 
vitrectomy with membrane peeling, endolaser, silicone oil injection and 
intraocular lens implantation (Table-5; Chart-7). 
Table -5  Type of surgery performed in patients undergoing pars 
plana vitrectomy for diabetic retinopathy complications 
Surgical procedure performed Number of eyes 
PPV +EL 
PPV + IOL 
PPV + MP + EL 
PPV + MP + EL + SOI 
PPV + MP + EL + IOL 
PPV +MP + EL + SOI + IOL 
6 
6 
7 
21 
4 
3 
 
PPV – Pars plana vitrectomy  IOL – Intraocular lens 
MP – Membrane peeling EL – Endolaser 
SOI – Silicone oil 
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Chart 7.   Surgical procedure performed in patients with 
proliferative diabetic retinopathy 
 
PPV – Pars plana vitrectomy  IOL – Intraocular lens 
MP – Membrane peeling EL – Endolaser 
SOI – Silicone oil 
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5.  Intraoperative complications 
 In this study, of the 47 eyes which underwent vitrectomy, four (8%) 
eyes had severe intraoperative bleeding and eight (17%) eyes had 
iatrogenic retinal break (one from vitreous hemorrhage group and seven 
from tractional retinal detachment group). Of the four (8%) eyes which 
encountered intraoperative bleeding, one each was from different groups. 
(Table – 6)  
Table-6  Intra operative complications in patients undergoing pars 
plana vitrectomy for diabetic retinopathy complications 
Group Bleeding (no. of 
patients) 
Retinal break (no of 
patients) 
VH 
TRD 
TRD +VH 
Macular edema 
1 
1 
1 
1 
1 
4 
3 
- 
VH – Vitreous hemorrhage   TRD – Tractional retinal detachment 
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6.  Post operative complications 
 Of the 47 eyes which underwent vitrectomy, ten (21%) eyes had 
significant post operative complications. Three (6%) eyes had recurrent 
vitreous hemorrhage, three (6%) eyes had retinal break detected post- 
operatively, two (4%) eyes presented with severe macular edema (500µ on 
OCT), one eye developed combined rhegmatogenous and tractional retinal 
detachment detected post operatively and one eye developed cataract. 
(Table-7) 
 
Table-7  Postoperative complications in patients undergoing pars 
plana vitrectomy for diabetic retinopathy complications 
Group Retinal 
break 
Recurrent 
vitreous 
hemorrhage 
Combined 
RRD + 
TRD 
Macular 
edema 
Cataract 
VH 
TRD 
TRD + VH 
VMT 
2 
1 
- 
- 
2 
- 
1 
- 
1 
- 
- 
- 
- 
- 
1 
1 
- 
1 
- 
- 
 VH – vitreous hemorrhage      TRD – Tractional retinal detachment 
VMT- Vitreomacular traction  
 RRD – Rhegmatogenous retinal detachment 
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7.  Visual acuity and anatomical outcomes  
a.  Immediate post operative period 
 In this study of 47 eyes which underwent pars plana vitrectomy, the 
mean post operative BCVA was (~6/60) 0.10 ± 0.02 in decimals (Table-8). 
Forty-two (89%) eyes out of 47 eyes had a stable retina postoperatively 
while three (6%) eyes developed retinal detachments (who were not 
willing for second surgery) and two (4%) eyes had severe macular edema. 
b.  At 1 month post operative period 
  Of the 47 eyes, the average BCVA at 1 month post operative period 
was (~6/60) 0.15 ± 0.03 in decimals (Table-8). The retina was well 
attached in 42(89%) eyes at 1 month follow up whereas two (4%) eyes had 
macular edema and three (6%) eyes had retinal detachment at 1 month. 
c.  At 3 months follow up 
 At 3 months following surgery, of the 47 eyes which underwent pars 
plana vitrectomy for diabetic retinopathy, 42(89%) eyes had a stable well 
attached retina while three (6%) eyes had retinal detachment and two (4%) 
eyes had persistent macular edema at the end of the follow up. The mean 
best corrected visual acuity at the end of 3 months was (~6/36) 0.22 ± 0.21 
in decimals (Table-8). 
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Table-8  Mean post operative visual acuity in patients undergoing 
pars plana vitrectomy for diabetic retinopathy 
complications 
Post operative visit  Visual acuity range in 
decimals (±SD) 
Approximate Snellens 
equivalent 
Immediate 
1 month  
3 month 
0.10 ± 0.02 
0.15 ± 0.03 
0.22 ± 0.21 
6/60 
6/60 
6/36 
 
8.  Comparison of pre operative and post operative visual outcome 
 In this study of the 47 eyes which underwent pars plana vitrectomy, 
the mean pre operative visual acuity(decimals) was 0.05 ± 0.009 (~3/60) 
while the mean  post operative visual acuity immediately post surgery was 
0.10 ± 0.02 (~6/60) which was statistically significant (‘t’[d.f :92] = 2.3 ; 
p= 0.003) (Table-9/Chart-7). 
In the vitreous hemorrhage group the mean pre operative visual 
acuity (decimals) was 0.02 ± 0.006 (~1/60) while the mean post operative 
visual acuity (decimals) immediately post surgery was 0.08 ± 0.03 (~5/60) 
(‘t’ [d.f :48] = 1.9; p= 0.02). At the end of the 1 month postoperative 
period, the mean visual acuity (decimals) was 0.11 ± 0.03 (~6/60) which 
was significantly better than the mean pre-operative value (‘t’ [d.f : 48] 
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=2.9; p=0.001). When compared at the end of 3 months the visual acuity 
(decimals) was 0.18 ± 0.04 (~ 6/36) which was significantly better than the 
mean pre- operative value (Student’s’s ‘t’ test) (‘t’ [d.f :48] = 3.9; 
p=0.001) (Table-9; Chart-8). 
 In the tractional retinal detachment group the mean pre operative 
visual acuity was 0.06 ± 0.02 (~4/60); at the immediate post operative visit 
the mean visual acuity, (decimals) was 0.09 ± 0.01 (~5/60) ‘t’ [d.f : 30] = 
5.3; p=0.06 (approaching statistical significance). At 1 month post- op, the 
mean visual acuity was 0.17 ± 0.05 (~6/36) which was significantly better 
than the mean pre-operative value  (‘t’ [d.f :30] =1.9;  p=0.04). Similarly, 
at the end of 3 months follow up, the mean post operative visual acuity was 
0.21 ± 0.06 (~6/36) which when compared with the pre operative visual 
acuity, was statistically significant (‘t’ [d.f :30] = 2.3; p=0.01) (Table-9; 
Chart-8). 
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Table-9  Comparison of pre and postoperative visual acuity 
Duration 
All eyes Vitreous hemorrhage Tractional retinal detachment 
VA in 
decimals 
Statistical 
analysis 
p value 
VA in 
decimals 
Statistica
l analysis 
p value 
VA in 
decimals 
Statistical 
analysis 
p value 
Pre operative 
Immediate PO 
1 month PO 
3 month PO 
0.05±0.009 
0.10±0.02 
0.15±0.03 
0.22±0.21 
 
0.003* 
0.00004** 
0.00004*** 
0.02±0.006 
0.08±0.03 
0.11±0.03 
0.18±0.04 
 
0.02* 
0.001** 
0.0001*** 
0.06±0.02 
0.09±0.01 
0.17±0.05 
0.21±0.06 
 
0.05* 
0.04** 
0.01*** 
PO – Post operative    VA – Visual acuity 
* - Pre operative visual acuity vs immediate post operative VA 
** - Pre operative VA vs 1 month post operative VA 
*** - Pre operative VA vs 3 month post operative VA 
Statistical Analysis – Student’s ‘t’ test 
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Chart 8.  Comparison of improvement in pre and post-operative 
visual acuity between different groups 
 
VH – Vitreous hemorrhage 
TRD – Tractional retinal detachment 
 
 
 
52 
9.  Improvement in mean visual acuity between groups 
 In this study, the improvement in visual acuity after surgery was 
compared between 25(53%) eyes that had vitreous hemorrhage versus 
22(47%) eyes without vitreous hemorrhage. Also, improvement in visual 
acuity was compared between 16(34%) eyes that had tractional retinal 
detachment and 31(67%) eyes those that did not have tractional retinal 
detachment. The mean post operative visual acuity (decimals) at 3 months 
in vitreous hemorrhage group was (~6/60) 0.18 ± 0.12 while the mean 
BCVA (decimals) in the group without vitreous hemorrhage was (~6/36) 
0.23 ± 0.01 (Table-10; Chart-9). The mean BCVA (decimals) in tractional 
retinal detachment group was (~6/36) 0.21 ± 0.01 and the mean BCVA 
(decimals) in the group without tractional retinal detachment was (~6/36) 
0.20 ± 0.12 (Table-11; Chart-10).  
 When the mean visual acuity in the vitreous hemorrhage group was 
compared with that in the group without vitreous hemorrhage 
immediately after surgery the difference  was  not statistically significant 
(p=0.1). Similarly no significant differences were noted when compared at 
the end of 1 month (p=0.1) and at the end of 3 months (p=0.4)  (Table-10). 
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Similarly when the mean visual acuity in the tractional retinal 
detachment group was compared with that in the group without tractional 
retinal detachment, no significant differences were noted immediately post 
operatively (p=0.8), at the end of one month (p=0.6) and at 3 months 
(p=0.8) (Table-11). 
Table-10  Comparison of mean post operative visual acuity between 
group with vitreous hemorrhage and group without 
vitreous hemorrhage at various post-operative visits in 
patients undergoing pars plana vitrectomy. 
Post operative 
visit 
Mean best corrected visual acuity 
(decimals) Statistical 
analysis 
(Student’s ‘t’ 
test) 
Vitreous 
hemorrhage 
n=25 
No vitreous 
hemorrhage 
n=22 
Immediate 
1 month 
3 months 
0.08 ± 0.03 
0.11 ± 0.03 
0.18 ± 0.12 
0.15 ± 0.11 
0.21 ± 0.001 
0.23 ± 0.01 
p= 0.1 
p= 0.1 
p= 0.4 
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Chart 9.  Comparison of mean post-operative visual acuity between 
groups with vitreous hemorrhage and group without 
vitreous hemorrhage at various intervals 
 
VH- Vitreous hemorrhage 
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Table-11  Comparison of mean post operative visual acuity between 
group with tractional retinal detachment and group 
without tractional retinal detachment at various post 
operative visits 
 
Post operative 
visit 
Mean BCVA (decimals) Statistical 
analysis 
(Student’s ‘t’ 
test) 
TRD group 
(n=16) 
Group without 
TRD (n=31) 
Immediate 
1 month 
3 months 
0.09 ± 0.01 
0.17 ± 0.001 
0.21 ± 0.01 
0.10 ±0.01 
0.13 ± 0.03 
0.20 ±0.12 
p= 0.8 
p= 0.6 
p= 0.8 
VH – Vitreous hemorrhage 
TRD – Tractional retinal detachment  
BCVA-Best corrected visual acuity 
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Chart 10.   Comparison of mean post-operative visual acuity between 
groups with and without tractional retinal detachment at 
various post-operative intervals 
 
TRD – Tractional retinal detachment 
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10.  Comparison of quantum of change in visual acuity  
a.  In group with Vitreous hemorrhage vs group without vitreous 
hemorrhage 
 In this study, 25(53%) eyes underwent pars plana vitrectomy for 
vitreous hemorrhage and the mean BCVA (decimals) post-operatively was 
0.06 ± 0 (immediate post-operative), 0.09 ± 0.08 (1 month post-operative) 
and 0.17 ± 0.09 (3 months post-operative). Of the 22(47%) eyes which had 
no vitreous hemorrhage, the mean BCVA (decimals) post operatively, was 
0.11 ± 0 (immediate), 0.13 ± 0.02 (1 month post operative), and 0.14 ± 
0.09 (3 months post-operative) (Table-12).  
  The quantum of change in visual acuity did not differ significantly 
between the two groups (with vitreous hemorrhage versus without vitreous 
hemorrhage) at immediate post operative period (p=0.06), at 1 month 
(p=0.2) and at 3 months post operatively (p=0.9 (Table-12). 
b.  In group with Tractional retinal detachment vs group without 
tractional retinal detachment 
 In this study, 16(34%) eyes underwent vitrectomy for tractional 
retinal detachment (TRD), and the mean post operative BCVA (in 
decimals) immediate post-operative was 0.07 ± 0, at 1 month was 0.13 ± 
0.05, and at 3 months was 0.16 ± 0.05. Of the 31(67%) eyes which had no 
TRD the mean BCVA (in decimals) was 0.08 ± 0 immediate post-
operative, 0.11 ± 0.02 at 1 month post-operative and was 0.17 ± 0.02 at 3 
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months post-operative, differences were not statistically significant (p=0.9) 
(Table-13). 
 Similarly, the quantum of change in visual acuity did not differ 
significantly between the TRD and no TRD groups at immediate post 
operative period (p=0.9), at 1 month post-operatively (p=0.6) and at 3 
months follow up  (Student’s ‘t’ test) (p=0.9) (Table-13). 
Table-12  Comparison of quantum of change in mean best corrected 
visual acuity in groups with vitreous hemorrhage and 
without vitreous hemorrhage  
Post operative 
visits 
Mean quantum of change in 
BCVA Statistical 
analysis 
(Student’s ‘t’ 
test) 
Vitreous 
hemorrhage 
group( n=25) 
No vitreous 
hemorrhage 
group( n=22) 
Immediate 
1 month 
3 month 
0.06 ± 0.0 
0.09 ± 0.08 
0.17 ± 0.09 
0.11 ± 0.0 
0.13 ± 0.02 
0.14 ± 0.09 
p= 0.3 
p= 0.2 
p= 0.9 
BCVA – Best corrected visual acuity 
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Table-13  Comparison of quantum of change in mean best corrected 
visual acuity in group with tractional retinal detachment 
and without tractional retinal detachment 
Post operative 
visits 
Mean quantum of change in 
BCVA Statistical analysis 
(Student’s ‘t’ 
test) Group with TRD n=16 
Group without 
TRD n=31 
Immediate 
1 month 
3 month 
0.07 ± 0.0 
0.13 ± 0.05 
0.16 ± 0.05 
0.08 ± 0.0 
0.11 ± 0.02 
0.17 ± 0.02 
p= 0.9 
p= 0.6 
p= 0.9 
 
TRD – Tractional retinal detachment 
BCVA- Best corrected visual acuity 
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11.  Comparison of proportion of eyes that had improvement in 
visual acuity in different sub groups  
In the present study, pars plana vitrectomy was done for 25 eyes 
with vitreous hemorrhage and 22 eyes without vitreous hemorrhage. On 
the first post-operative day, 19(76%) of eyes in the vitreous hemorrhage 
group and 11(50%) of eyes in the non-vitreous hemorrhage group showed 
improved visual acuity, this difference approached statistical significance 
(χ2 [ d.f = 1]= 3.5; p=0.06). At the end of one month and at the end of three 
months, 18 eyes in each group (72% of eyes in vitreous hemorrhage group, 
82% of eyes in non-vitreous hemorrhage group showed improved visual 
acuity; this difference was not statistically significant.  
In the same study, pars plana vitrectomy was done for 16 eyes with 
tractional retinal detachment and 31 eyes with no tractional retinal 
detachment. On the first post operative day, 7(44%) of eyes with tractional 
retinal detachment and 23(74%) of eye in the no tractional retinal 
detachment group showed improved  visual acuity. This difference was 
statistically significant (χ2 [d.f =1]= 4.2; p=0.04). At the end of 1 month 
and at the end of 3 months, 12(75%) eyes from tractional retinal 
detachment group and 24(77%) eyes from no tractional retinal detachment 
group showed improved visual acuity, this difference was not statistically 
significant. 
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Table-14  Comparison of numbers of eyes with improved visual 
acuity in eyes with and without vitreous hemorrhage 
Post 
operative 
visit 
Vitreous hemorrhage No vitreous hemorrhage Statistical 
analysis (chi-
square test) Improved Not improved Improved 
Not 
improved 
Immediate 
1 month 
3 month 
19 
18 
18 
6 
7 
7 
11 
17 
18 
11 
5 
4 
p=0.06 
p=0.6 
p=0.4 
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Table-15  Comparison of numbers of eyes with improved visual 
acuity in eyes with and without Tractional Retinal 
Detachment 
Post 
operative 
visit 
TRD NO TRD Statistical 
analysis 
(chi-
squared 
test) 
Improved Not improved Improved 
Not 
improved 
Immediate 
1 month 
3 month 
7 
12 
12 
9 
4 
4 
23 
23 
24 
8 
8 
7 
p=0.04 
p=0.9 
p=0.8 
TRD- Tractional retinal detachment 
 
 
  
Figure 5.  (a) Colour fundus photograph of a study patient showing 
vitreous haemorrhage. (b) Colour fundus photograph of the 
same eye as in Fig 5a following pars plana vitrectomy. 
  
a 
b 
  
Figure 6.  (a) Colour fundus photograph of a study patient showing dense 
vitreous haemorrhage. (b) Colour fundus photograph of the 
same eye as in Fig 6a following pars plana vitrectomy with 
silicone oil. 
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Figure 7.  (a) Colour fundus photograph of a study patient showing 
fibrovascular proliferation with tractional retinal detachment 
involving the macula. (b) Colour fundus photograph of the 
same eye as in Fig 7a following pars plana vitrectomy showing 
stable retina with silicone oil. 
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Figure 8.  (a) Colour fundus photograph of a study patient showing 
tractional retinal detachment with vitreous haemorrhage. (b) 
Colour fundus photograph of the same eye as in Fig 8a 
following pars plana vitrectomy showing well attached retina 
with areas of laser photocoagulation. 
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Figure 9.  (a) Colour fundus photograph of a study patient showing 
fibrovascular proliferation and dense premacular 
haemorrhage. (b) Colour fundus photograph of the same eye as 
in Fig 9a following pars plana vitrectomy showing stable retina 
with areas of laser photocoagulation. 
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Figure 10.  (a) Optical coherence tomography picture of a study eye 
showing recalcitrant macular edema. (b) Optical coherence 
tomography of the same eye as in Fig 10 a following pars plana 
vitrectomy showing reduction in macular edema. 
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Figure 11.  (a) Optical coherence tomography picture of a study eye 
showing vitreomacular traction. (b) Optical coherence 
tomography of the same eye as in Fig 11 a following pars plana 
vitrectomy showing reduction in macular edema. 
a 
b 
Discussion 
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DISCUSSION 
 Pars plana vitrectomy (PPV) in proliferative diabetic retinopathy 
(PDR) can be effective in clearing media opacities (such as blood) and 
relieving traction from fibrovascular tissue in the retina. However, PPV in 
eyes with PDR can be associated with severe and vision-threatening 
complications, and the final outcome, in terms of anatomical and visual 
forms depend on several factors. Hence, it is important to determine the 
visual prognosis associated with PPV for various indications in PDR so 
that an optimum course of treatment can be chosen. 
A landmark trial was conducted in the year 1976, known as Diabetic 
Retinopathy Vitrectomy Study20 (DRVS), in which two randomized trials 
were done to determine whether   (i) early vitrectomy was preferable to 
delayed vitrectomy in eyes with severe vitreous hemorrhage due to PDR 
and (ii) early vitrectomy is preferable in eyes with PDR without vitreous 
hemorrhage. The study concluded that early vitrectomy is recommended 
for eyes with severe vision loss from non-clearing vitreous hemorrhage of 
at least one month duration in patients with type 1 DM, or in one-eyed 
patients regardless of the type of diabetes. Early  vitrectomy may also be 
recommended for eyes with advanced active PDR, particularly when there 
is presence of extensive neovascularization. 
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 In recent years, advances in vitreo retinal surgery and the 
development of endolaser have changed some of the recommendations of 
the DRVS. Several advances in surgery, including transconjunctival 
sutureless vitrectomy (23 and 25 G) and the availability of  high speed 
cutters, microcannulas, insertion trocars,  xenon light source, wide angle 
fundus viewing systems (e.g;  binocular indirect operating microscope and 
erect indirect binocular ophthalmic system), pulsed electron avalanche 
knife, perflurocarbon liquids, expansile gases, and anti – VEGF adjuncts. 
Transconjunctival sutureless vitrectomy provides earlier visual 
improvement (as early as seven days) and less surgically-induced 
astigmatism (about -1.50 Dioptre) than conventional vitrectomy. These 
advances have led to improved results, in turn leading to PPV being 
performed more and more often in PDR with associated visual 
complications. 
 The current study was a prospective interventional study done to 
document the various indications for PPV in patients presenting with PDR, 
to determine the anatomical results and functional visual outcomes 
following vitrectomy in eyes  with diabetic retinopathy, to elucidate factors 
possibly influencing the results obtained, and to study the safety of PPV in 
eyes with diabetic retinopathy by documenting intraoperative and post-
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operative complications, and to elucidate the  factors responsible for such 
complications.  
With reference to demographic characteristics in this study, the 
patients who underwent PPV for treatment of complications due to diabetic 
retinopathy were almost equally matched for gender and laterality of the 
eye (Chart 1&2) undergoing PPV. The mean age of the patients in the 
study who underwent vitrectomy was 55 years, while 65% of the patients 
enrolled in the study had suffered from diabetes for around 10 years. In 
this study, 52% of the patient had other associated (co-morbid) systemic 
diseases along with diabetes (Table-2). Most of the patients who 
underwent vitrectomy had type II diabetes (85%), but the duration of 
evolution of the disease was similar in patients with type I and type II 
diabetes (7 and 9 years).  
 Ferreira et al.40 (2011) in their study on vitrectomy in diabetic 
retinopathy reported on 84 eyes that underwent surgery. The mean age of 
the patients who underwent vitrectomy was 58 years (similar to that of the 
patients in  the present study); the mean duration of diabetes up to the time 
of vitrectomy was 21 years for type I diabetes and 18 years for type II 
diabetes. Most of the patients who underwent vitrectomy had type II 
diabetes (n=61), which is similar to the pattern noted in the present study.  
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With reference to indications for vitrectomy Thompson et al.43 
(1986) in their study of vitrectomy in diabetic retinopathy, found that 35% 
of their patients had vitreous hemorrhage, 36% had tractional retinal 
detachment (TRD), 17% had combined tractional and rhegmatogenous 
retinal detachment and 12% had fibrovascular proliferation as indications 
for vitrectomy due to complications of diabetic retinopathy. Tony Ho et 
al.41 (1992), in their study, found that the most common indications for 
vitrectomy in diabetic retinopathy were severe non-clearing vitreous 
hemorrhage, tractional retinal detachment involving macula, combined 
rhegmatogenous and tractional detachment, progressive fibrovascular 
proliferation and dense premacular hemorrhage. Helbig H et al.42 (2007), 
in their study, reported that the typical indications for vitrectomy were 
vitreous hemorrhage, TRD, combined rhegmatogenous and tractional 
retinal detachment and tractive macular edema.   
In the current study the most common indication for PPV was found 
to be vitreous hemorrhage (53%), followed by TRD (34%); 4% of eyes had 
recalcitrant macular edema and another 4% had non-clearing premacular 
hemorrhage (Table-3; Chart-6). 
Coming to the surgical procedure used, Qamar et al.45 (2003), 
performed PPV for patients with TRD without retinal break; all the 
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patients (84 eyes) underwent PPV with membrane peeling with endolaser. 
There authors concluded that TRD without retinal breaks can be treated by 
PPV without internal tamponade. In another study, Castellarin et al.46 
(2003) concluded that PPV with silicone oil infusion is useful in severely 
affected eye with PDR even in the presence of rubeosis iridis and 
neovascular glaucoma, and also in cases of previously failed vitrectomy. In 
yet another study, Canan et al.47 (2003) observed that the combined 
operation of PPV, phacoemulsification, and intraocular lens implantation 
was safe and effective for patients with PDR; visual outcome and 
complications depended on underlying posterior segment pathology and 
were not related to the combined procedure technique. Interestingly 
Teresio Avitabile et al.44 (2011) compared PPV with pan retinal 
photocoagulation for severe PDR. In their study, one group of  patients 
underwent PPV with membrane peeling with internal limiting membrane 
peeling while the other group underwent laser photocoagulation. These 
investigators concluded that surgery can be deferred in eyes with TRD not 
involving the macula until progression threatens the vascular centre. 
 In the current study all 47 eyes underwent a standard 20G three port 
PPV of which 45% underwent vitrectomy with membrane peeling with 
silicone oil injection while another 48% underwent vitrectomy without 
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silicone oil injection; the remaining 7% underwent a combined procedure 
of pars plana vitrectomy with phacoemusification alone (Table-5; chart-7). 
Use of silicone oil tamponade in the current study did not depend on the 
indications for vitrectomy but on complications encountered in the 
particular case.  
As with any surgery surgical complications may be encountered 
when performing PPV. West et al.49 (2000), in their study, found that it 
was not uncommon for fibrovascular ingrowths at the sclerotomy sites to 
be responsible for recurrent vitreous hemorrhage in eyes that had 
undergone PPV. In another study, Kamura et al.48 (2013) observed that 
29% of patients undergoing vitrectomy for fibrovascular membrane 
proliferation developed iatrogenic breaks during membrane dissection, 
while oral dialysis was another intraoperative complication. Post- 
operatively, 4% of patients had recurrent vitreous hemorrhage, recurrent 
retinal detachment and sclerotomy site fibrovascular proliferation. 
 In the present study the most common intraoperative complication, 
encountered during vitrectomy in eyes with TRD was iatrogenic retinal 
breaks, which occurred in 17% of 47 eyes, followed by intraoperative 
bleeding (Table-6). Post-operatively, about 6% of patients in this study 
presented with recurrent vitreous hemorrhage and retinal break and 4% had 
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severe macular edema > 500µ on OCT. In the present series, the 
complication of fibrovascular ingrowth causing recurrent vitreous 
hemorrhage was not noted in any of the operated eyes, possibly due to the 
short period of follow-up in many of the cases. 
Surgical outcomes of PPV for diabetic retinopathy complications 
may be varied. Machemer et al.51 (1981) in their study on vitrectomy for 
diabetic retinopathy, found that visual improvement occurred in 59% of the 
eyes in which the retina was stable, while in 25% of patients there was 
retinal detachment, which resulted in  visual improvement in only 46% of 
eyes; the total success rate was 51%.The main causes for bad prognosis 
were rubeosis of the iris and posterior retinal detachment with 42% of all 
eyes exhibiting some degree of rubeosis of iris. Most of the preoperative 
eyes (71%) which had rubeosis presented postoperatively also with 
rubeosis51. In another study, Karel et al.50 (1994) observed that 57% of  
patients had a good anatomical success, and functional success with visual 
acuity 0.01 and better in 32%. Functional failures were due to retinal 
redetachment in 43%, secondary glaucoma in 9%, and retinal ischemia in 
13%; the functional success rate decreased with follow-up from 67% after 
six months to 50% by 60 months50. In yet another study, Qamar et al.45 
(2003) observed successful retinal reattachement in 92% of operated eyes, 
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in those patients, the retina was stable and attached till the end of the one-
year follow-up. Improvement in best corrected visual acuity was seen in 
75%; mean improvement in best corrected visual acuity was 2.00+1.24 
lines at baseline to 1.24+1.22 (P<0.05) at the end of the follow-up45. 
 In the present study 89% of eyes were found to have stable, well 
attached retinas postoperatively, while 6% of patients had retinal 
detachment and 4% had persistent macular edema at the end of the follow 
up period. These results are comparable to those of other studies, 
suggesting that PPV is a useful and successful surgical technique in PDR. 
Moreover visual acuity improved significantly after surgery (p=0.00004). 
This improvement was seen across all indications for vitrectomy including 
non clearing vitreous hemorrhage (p=0.0001) and tractional retinal 
detachment (p=0.01) (Table-9; Chart-8). Eyes with tractional  retinal 
detachment tended to gain visual acuity at a slower pace with improvement 
evident only after one month after surgery. Use of silicon oil tamponade 
did not affect visual outcomes. 
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The present study had some limitations: 
(i) All the patients in this study underwent a standard 20G pars plana 
vitrectomy performed by multiple surgeons; more recent advances 
like microincision vitrectomy surgery (MIVS) were not performed.  
(ii) Only a small sample size could be studied due to the limited time 
duration of the study. 
(iii) In the current study, the follow-up period was only 3 months, which 
is shorter than that reported in other studies. 
Summary 
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SUMMARY 
  The study entitled ‘Indications efficacy and outcome of pars plana 
vitrectomy in diabetic retinopathy’, was performed at the Retina clinic, 
Joseph Eye Hospital, Tiruchirapalli, during the period from May 2012 to 
June 2013.  
 Each patient undergoing pars plana vitrectomy for diabetic 
retinopathy who did not have any exclusion criterion and who provided 
informed consent was enrolled. All the patients first underwent a detailed 
clinical examination (baseline), which included determination of best 
corrected visual acuity (BCVA) for distance using Snellens chart, 
intraocular pressure (IOP) measured by applanation tonometry, slit lamp 
examination, fundus examination using + 90D lens (after dilatation), 
fundus photography and measurement of macular edema, screening for 
vitreomacular traction by optical coherence tomography (OCT), ultrasound 
B scan, and fundus fluorescein angiography.  
 All the patients enrolled in the study underwent a standard 20 G pars 
plana vitrectomy for the complications of proliferative diabetic 
retinopathy.  The intraoperative and post-operative complications were 
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documented and these patients were followed up at immediate, 1 month 
and 3 months post-operatively.  
 During the follow-up period, eyes were subjected to visual acuity 
measurement, fundus examination, IOP measurement, fundus photography 
and optical coherence tomography. 
 Fourty seven eyes of 46 patients (26 males, 20 females) were 
enrolled in the study. The mean age of the patients was 55.04±9.6 years; 
most of the patients in the study were in the age group of 41 to 50 years of 
age. In this study, 65% of patients who suffered from complications of 
diabetic retinopathy had suffered from diabetes for less than 10 years; 52% 
of patients (who all had diabetes) also suffered from other coexisting 
diseases; 87% of the patients were on oral hypoglycemic agents as a 
treatment for diabetes. 
 Of the 47 eyes that underwent vitrectomy, 53% of eyes had vitreous 
hemorrhage and 34% had tractional retinal detachment as a complication 
of proliferative diabetic retinopathy (PDR).  In patients with vitreous 
hemorrhage the average BCVA was 0.019 ± 0.01 (~1/60), in case of 
tractional retinal detachment the average BCVA was 0.070 ± 0.029 
(~4/60). 
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 In this study, the most common surgical procedure performed was 
pars plana vitrectomy with membrane peeling along with endolaser and 
silicon oil injection (45%), 28% of the eyes had intraocular implantation 
along with vitrectomy. Intra-operatively 17% of the eyes, which were 
mostly from the tractional retinal detachment group, developed iatrogenic 
retinal break. Twenty-one percent of the eyes in this study had significant 
complications post-operatively which included recurrent vitreous 
hemorrhage and combined rhegmatogenous and tractional retinal 
detachment. 
 Post-operatively, of the 47 eyes which underwent vitrectomy, 42 
(89%) eyes had a stable well- attached retina; with the mean best corrected 
visual acuity at the end of 3 months being (~6/36) 0.22 ± 0.21 in decimals. 
In the vitreous hemorrhage group, the mean BCVA (decimals) was 0.02 ± 
0.006 (~1/60), while 3 months after the surgery, the mean BCVA 
(decimals) was 0.18 ± 0.04 (~ 6/36); this improvement was statistically 
significant (‘t’ [d.f :48] = 3.9; p=0.001). Similarly in the tractional retinal 
detachment group the mean pre operative BCVA  was 0.06 ± 0.02 (~4/60), 
and at the end of 3 months follow- up, the mean post-operative BCVA  
was 0.21 ± 0.06 (~6/36); this difference was statistically significant (‘t’ 
[d.f :30] = 2.3; p=0.01). 
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 The mean post-operative BCVA (decimals) at 3 months in the 
vitreous hemorrhage group was (~6/60) 0.18 ± 0.12 which was comparable 
with the mean BCVA (decimals) in the group without vitreous hemorrhage 
(~6/36) 0.23 ± 0.01(p=0.4). Similarly, the mean BCVA (decimals) in the 
tractional retinal detachment group was (~6/36) 0.21 ± 0.01, which did not 
differ significantly from the mean BCVA (decimals) in the group without 
tractional retinal detachment, which was (~6/36) 0.20 ± 0.12. 
Comparing the proportion of eyes that showed improvement in 
visual acuity, on the first post-operative day, there was no difference 
between eyes with and without vitreous hemorrhage (p= 0.06); however, 
eyes without tractional retinal detachment (TRD) were more likely to have 
improved visual acuity than eyes without TRD (p=0.04), but these 
differences were seen only on the first post-operative day, and were not 
sustained at 1 month and 3 month follow up. 
Conclusion 
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CONCLUSIONS 
 Vitreous hemorrhage and tractional retinal detachment are the most 
common indications for pars plana vitrectomy in diabetic 
retinopathy. 
 Patients with vitreous hemorrhage tend to present with significant 
worsening of visual acuity than other complications of proliferative 
diabetic retinopathy. 
 Pars plana vitrectomy in proliferative diabetic retinopathy results in 
a significant improvement of visual acuity. 
 Visual acuity improvement is seen across all indications of 
vitrectomy. 
 Visual acuity improvement is sustained over a short-term follow up. 
 Visual acuity in eyes with tractional retinal detachment tends to 
improve more gradually when compared to eyes with vitreous 
hemorrhage. 
 Vitrectomy in proliferative diabetic retinopathy may be associated 
with significant vision-threatening complications 
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Proforma 
 PROFORMA 
Indications Efficacy and outcomes of pars plana 
vitrectomy in diabetic retinopathy 
 
 Institute of Ophthalmology 
  Joseph Eye Hospital 
 Tiruchirappalli. 
 
Patient number :                                 M.R. Number : 
Date   : 
Name   :                                                 Age : 
Sex   :  
Address  : 
 
Telephone number : 
Diagnosis  : 
 
 
Personal history : 
DM & Duration : 
HT 
CRF 
CAD 
Others 
Treatment history : 
  
Allergies  : 
Indication for vitrectomy: 
Surgery details 
Type  : 
Tamponade : 
Endolaser : 
Intraoperative complications : 
Post-operative complications : 
 
Ocular examination 
Parameters Baseline Immediate 
POD 
1 month 3 months 
Date: 
BCVA: 
Distance 
Near 
IOP: 
OCT: 
Retina status: 
    
 
 
Master Chart 
